Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

John C. McAuliffe, Alexander J.F. Lazar, Dan Yang, Dejka M. Steinert, Wei Qiao, Peter F. Thall, A. Kevin Raymond, Robert S. Benjamin, Jonathan C. Trent

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: Imatinib mesylate (imatinib) has revolutionized clinical outcomes of patients with advanced gastrointestinal stromal tumor (GIST). However, the degree of individual benefit varies, and little is known about prognostic factors for these patients. Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression. Experimental Design: Using tissue microarray technology, we analyzed 53 imatinib-naive GISTs for vascular endothelial growth factor (VEGF) expression from patients who then received imatinib. In multivariate analyses, we evaluated overall survival (OS) and progression-free survival (PFS) of these patients based on putative prognostic factors, including VEGF expression. In a separate study, 12 matched pre-imatinib and post-imatinib GIST patient specimens and two human GISTcell lines were assessed for VEGF production in response to imatinib. Results: Independent of kit genotype, patients with GIST expressing high VEGF had inferior median PFS (7.1 months versus 29 months, P = 0.42) and median OS (20 months versus not reached at >50 months; P = 0.02) compared with weak or nonexpressers of VEGF. Non-exon 11 kit mutation predicted inferior PFS but not OS. High mitotic rate was marginally predictive of improved OS. Imatinib resulted in decreased production of VEGF in only a subset of GIST patients (2 of 12) and both cell lines. Conclusions: We present a study to address the prognostic factors for patients with GIST in the imatinib era. We present a rationale to consider exploration of a front-line therapy of GIST with a regimen targeting both Kit and VEGFR based on the presence of tumor VEGF levels.

Original languageEnglish (US)
Pages (from-to)6727-6734
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number22
DOIs
StatePublished - Nov 15 2007
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Vascular Endothelial Growth Factor A
Disease-Free Survival
Vascular Endothelial Growth Factor Receptor
Survival
Imatinib Mesylate
Research Design
Multivariate Analysis
Genotype
Technology
Cell Line
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. / McAuliffe, John C.; Lazar, Alexander J.F.; Yang, Dan; Steinert, Dejka M.; Qiao, Wei; Thall, Peter F.; Raymond, A. Kevin; Benjamin, Robert S.; Trent, Jonathan C.

In: Clinical Cancer Research, Vol. 13, No. 22, 15.11.2007, p. 6727-6734.

Research output: Contribution to journalArticle

McAuliffe, John C. ; Lazar, Alexander J.F. ; Yang, Dan ; Steinert, Dejka M. ; Qiao, Wei ; Thall, Peter F. ; Raymond, A. Kevin ; Benjamin, Robert S. ; Trent, Jonathan C. / Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 22. pp. 6727-6734.
@article{06e8711ea64b49639b725733802783d7,
title = "Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate",
abstract = "Purpose: Imatinib mesylate (imatinib) has revolutionized clinical outcomes of patients with advanced gastrointestinal stromal tumor (GIST). However, the degree of individual benefit varies, and little is known about prognostic factors for these patients. Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression. Experimental Design: Using tissue microarray technology, we analyzed 53 imatinib-naive GISTs for vascular endothelial growth factor (VEGF) expression from patients who then received imatinib. In multivariate analyses, we evaluated overall survival (OS) and progression-free survival (PFS) of these patients based on putative prognostic factors, including VEGF expression. In a separate study, 12 matched pre-imatinib and post-imatinib GIST patient specimens and two human GISTcell lines were assessed for VEGF production in response to imatinib. Results: Independent of kit genotype, patients with GIST expressing high VEGF had inferior median PFS (7.1 months versus 29 months, P = 0.42) and median OS (20 months versus not reached at >50 months; P = 0.02) compared with weak or nonexpressers of VEGF. Non-exon 11 kit mutation predicted inferior PFS but not OS. High mitotic rate was marginally predictive of improved OS. Imatinib resulted in decreased production of VEGF in only a subset of GIST patients (2 of 12) and both cell lines. Conclusions: We present a study to address the prognostic factors for patients with GIST in the imatinib era. We present a rationale to consider exploration of a front-line therapy of GIST with a regimen targeting both Kit and VEGFR based on the presence of tumor VEGF levels.",
author = "McAuliffe, {John C.} and Lazar, {Alexander J.F.} and Dan Yang and Steinert, {Dejka M.} and Wei Qiao and Thall, {Peter F.} and Raymond, {A. Kevin} and Benjamin, {Robert S.} and Trent, {Jonathan C.}",
year = "2007",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-07-0895",
language = "English (US)",
volume = "13",
pages = "6727--6734",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

AU - McAuliffe, John C.

AU - Lazar, Alexander J.F.

AU - Yang, Dan

AU - Steinert, Dejka M.

AU - Qiao, Wei

AU - Thall, Peter F.

AU - Raymond, A. Kevin

AU - Benjamin, Robert S.

AU - Trent, Jonathan C.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Purpose: Imatinib mesylate (imatinib) has revolutionized clinical outcomes of patients with advanced gastrointestinal stromal tumor (GIST). However, the degree of individual benefit varies, and little is known about prognostic factors for these patients. Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression. Experimental Design: Using tissue microarray technology, we analyzed 53 imatinib-naive GISTs for vascular endothelial growth factor (VEGF) expression from patients who then received imatinib. In multivariate analyses, we evaluated overall survival (OS) and progression-free survival (PFS) of these patients based on putative prognostic factors, including VEGF expression. In a separate study, 12 matched pre-imatinib and post-imatinib GIST patient specimens and two human GISTcell lines were assessed for VEGF production in response to imatinib. Results: Independent of kit genotype, patients with GIST expressing high VEGF had inferior median PFS (7.1 months versus 29 months, P = 0.42) and median OS (20 months versus not reached at >50 months; P = 0.02) compared with weak or nonexpressers of VEGF. Non-exon 11 kit mutation predicted inferior PFS but not OS. High mitotic rate was marginally predictive of improved OS. Imatinib resulted in decreased production of VEGF in only a subset of GIST patients (2 of 12) and both cell lines. Conclusions: We present a study to address the prognostic factors for patients with GIST in the imatinib era. We present a rationale to consider exploration of a front-line therapy of GIST with a regimen targeting both Kit and VEGFR based on the presence of tumor VEGF levels.

AB - Purpose: Imatinib mesylate (imatinib) has revolutionized clinical outcomes of patients with advanced gastrointestinal stromal tumor (GIST). However, the degree of individual benefit varies, and little is known about prognostic factors for these patients. Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression. Experimental Design: Using tissue microarray technology, we analyzed 53 imatinib-naive GISTs for vascular endothelial growth factor (VEGF) expression from patients who then received imatinib. In multivariate analyses, we evaluated overall survival (OS) and progression-free survival (PFS) of these patients based on putative prognostic factors, including VEGF expression. In a separate study, 12 matched pre-imatinib and post-imatinib GIST patient specimens and two human GISTcell lines were assessed for VEGF production in response to imatinib. Results: Independent of kit genotype, patients with GIST expressing high VEGF had inferior median PFS (7.1 months versus 29 months, P = 0.42) and median OS (20 months versus not reached at >50 months; P = 0.02) compared with weak or nonexpressers of VEGF. Non-exon 11 kit mutation predicted inferior PFS but not OS. High mitotic rate was marginally predictive of improved OS. Imatinib resulted in decreased production of VEGF in only a subset of GIST patients (2 of 12) and both cell lines. Conclusions: We present a study to address the prognostic factors for patients with GIST in the imatinib era. We present a rationale to consider exploration of a front-line therapy of GIST with a regimen targeting both Kit and VEGFR based on the presence of tumor VEGF levels.

UR - http://www.scopus.com/inward/record.url?scp=36749006701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749006701&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0895

DO - 10.1158/1078-0432.CCR-07-0895

M3 - Article

VL - 13

SP - 6727

EP - 6734

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -